Introduction
Studies of patients with schizophrenia and of the mechanism of action of antipsychotics strongly support the view that there is a hyperactive dysregulation of the dopamine system in schizophrenia (evidence reviewed in references). [1] [2] [3] It has been proposed that this dopaminergic dysregulation is secondary to a primary glutamate deficiency in schizophrenia-the 'hypoglutamate' hypothesis of schizophrenia. [4] [5] [6] Direct evidence for a deficiency in the glutamate system in schizophrenia, or for the efficacy of glutamate agonist compounds is limited and conflicting. 7 However, the hypothesis remains attractive on the basis of animal models wherein challenges with non-competitive NMDA receptor antagonists, ketamine and PCP (thought to recapitulate the primary hypoglutamate state of schizophrenia), lead to the production of hyperlocomotion and sensorimotorgating deficits thought to be the underlying clinical abnormalities of schizophrenia. 8 Further it has been suggested that challenges with ketamine and PCP, since they model the puta-tively primary hypoglutamate state, are superior to the more conventional apomorphine or amphetamine models, which are thought to model a secondary hyperdopaminergic state. 9 Thus, it is suggested that these challenges provide a better model for the illness and constitute better models for identifying 'atypical' antipsychotics.
There is little question that the administration of ketamine and PCP leads to diverse changes in the dopamine, serotonin and other monoamine systems. 10, 11 According to the hypoglutamate hypothesis, these dopamine and serotonin effects are secondary to a primary hypoglutamate effect of ketamine and PCP. 5 However, a number of intriguing findings suggest that ketamine and PCP may not be selective models of a primary hypoglutamatergic state, but, may in fact have multiple actions. For example, a recent study by Tsukada et al found that ketamine administration resulted in a decrease in selective [ 11 C]-raclopride binding, without a concomitant increase in dopamine levels, raising the possibility that ketamine binds directly to D 2 receptors. 12 Similar concerns have also been raised about PCP, which has been shown to demonstrate direct protective effects at the serotonin 5-HT 2 receptor, suggesting direct or allosteric binding to the 5-HT 2 receptor. 13 Further, it has been suggested that ketamine and PCP may enhance endogenous levels of dopamine and serotonin via a direct effect on monoamine reuptake trans-porters, 14 a finding recently confirmed using cloned monoamine-reuptake receptors at clinically relevant doses. 15 Since the hypoglutamate model, as established by ketamine and PCP challenges, continues to be a popular model for the study of schizophrenia, the objective of the present study was to investigate the direct effects of ketamine and PCP on the dopamine D 2 and the serotonin 5-HT 2 receptor, particularly on the high-affinity states of these receptors as these are the functionally relevant states. 16 Once we observed that ketamine and PCP showed a relevant affinity for these receptors in clinical concentrations, and distinguished between the high-and low-affinity states of these receptors, we examined the effect of ketamine and PCP on [
35 S]GTP-␥-S to examine if they functioned as partial agonists on these receptors.
Methods

Tissue
Frozen rat brains were purchased (Pel-Freez Biologicals, Rogers, AR, USA) and stored at −70°C until used. The brain was partly thawed and the striata removed. The striata (or frontal cortex for serotonin 5HT 2A receptors) were homogenized with a Polytron (PT-10 probe, Brinkmann Instruments, Westbury, NY, USA; setting 5 out of a maximum of 10) for 5 s in buffer (4 mg frozen tissue per ml buffer). The buffer contained 50 mM Tris-HCl (pH 7.4 at 20°C), 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl 2 , 4 mM MgCl 2 and either 10 mM or 120 mM NaCl (as indicated in particular experiments). The homogenate was not washed or centrifuged because our previous work found that more than 30% of the receptors can be lost by these procedures. 17 For affinity studies involving cloned receptors we used the cloned dopamine D 2 long (human) receptor expressed in Chinese Hamster Ovary cell line (CHO), grown and treated as described previously. 18 The cells were suspended at 200 g protein ml −1 and the suspension was homogenized for 5 s (Polytron, setting 5). The rest of the procedures for cloned tissue were similar to that for brain tissue. ; final concentration of 0.2 nM in the incubation tube). Radical components were purchased from NEN Life Science Products, Boston, MA, USA. S-ketamine is known to have a higher affinity for the NMDA receptor than Rketamine. Since we had access to S-ketamine (provided courtesy of Prof HA Adams) but not R-ketamine, we examined the effects of S-ketamine vs the racemic mixture on the dopamine D 2 and NMDA receptors.
Radiolabeled ligands and reagents
Affinity determinations
The competition between a drug and a [ 3 H]ligand for binding at the receptors was done as follows. Each incubation tube (12 × 75 mm glass) received the following in order: 0.5 ml buffer with or without appropriate concentration of the test drug, 0.5 ml [
3 H]ligand and finally 0.5 ml of tissue homogenate. The tubes containing a total volume of 1.5 ml were incubated for 2 h at room temperature (20°C) after which the incubates were filtered using a 12-well cell harvester (Titertek, Skatron, Lier, Norway) and buffer-presoaked glass fiber filter mats (No. 7034, Skatron, Sterling, VA, USA). The filter mat was rinsed with buffer for 15 s (7.5 ml buffer). The filters were pushed out and placed in scintillation minivials (Packard Instruments, Chicago, IL, USA). The minivials received 4 ml each of scintillant (Ready Solve, Beckman Co, CA, USA) and were monitored 6 h later for scintillation in a Packard 4660 scintillation spectrometer at 55% efficiency. The experiments were carried out in duplicate and the affinity reported was based on the mean of 3-5 separate runs, unless otherwise stated the results are reported as mean ± standard error of mean (SEM).
The high-affinity states of G-linked receptors are sensitive to experimental conditions. As a result there is a wide range of values for the affinity of dopamine at the D 2 High site (the high-affinity state of this receptor), 2 nM 19 to 75 nM. 20 One reason for the wide range of dopamine affinities at the D 2 High site is that experiments use different levels of NaCl in the buffer. High levels of NaCl convert D 2 High receptors into their D 2 Low state, especially at 37°C, 21 obscuring the dissociation constant of dopamine at D 2 High, and increasing the error in the computer-assisted resolution of the dissociation constant at the high-affinity state. A low concentration of NaCl (10 mM) permits a clear demarcation of the D 2 High state as measured with [ 3 H]raclopride, with 40% of the receptors being in the highaffinity state. Thus, experiments to assess the affinity of ketamine and PCP to the high-affinity state were carried out under 10 mM conditions. To confirm that what was being measured was the high-affinity site of the receptor, the binding was carried out with and without 200 M guanilylimidodiphosphate (Gpp[NH]p) in the presence of the endogenous ligand. In each case it was documented that the low-affinity state was unaffected by Gpp[NH]p while the high-affinity state was totally eliminated (Figure 1 ).
Once the high-affinity state of each of the receptors was confirmed as above, experiments were carried out To confirm the effects on the high-affinity site via direct competition with the endogenous agonist ligand, we examined the effect of ketamine and PCP on the dopamine D 2 receptor high-affinity state of cloned dopamine D 2 long (human) receptors as expressed on CHO cells by competing against 4 nM [ 3 H]dopamine. The competition data were analysed, as previously described. 21 The data were examined to see whether a two-site fit was better than a one-site fit, and if the data conformed better to a two-site fit, the radioligand affinity for each site was determined.
[ 35 
S]GTP-␥-S incorporation
Agonist binding to G protein-coupled receptors leads to a coupling of GTP to the agonist-receptor complex, a process that can be measured using radiolabeled Molecular Psychiatry GTP-␥-S. 22 Gardner and Strange 23 have demonstrated that the stimulation of [ 35 S]GTP-␥-S binding in Chinese hamster ovary (CHO) cells expressing recombinant D2 long receptors provides a valid system for examining the binding and efficacy of agonists. D2 long receptors were expressed in CHO cells as described before. 18 The ability of ketamine and PCP to stimulate [
35 S]GTP-␥-S incorporation in cells expressing and devoid of D 2 receptors was measured as well as in the presence and absence of a dopamine D 2 antagonist (0.1-100 nM raclopride), along procedures described by Gardner and Strange. 23 Briefly, the cells were suspended in assay buffer (50 mM Tris, pH 7.4, 1 mM EDTA, 5 mM KCl, 4 mM MgCl 2 , 1.5 mM CaCl 2 , 10 mM NaCl and 10 M GDP) and then transferred to a glass test tube (12 × 75 mm) which received 0.25 ml of the test compound, 0.25 ml of [
35 S]GTP-␥-S (1250 Ci mmol −1 , ෂ0.2 nM) and 0.5 ml of cell suspension. The reaction mixtures were incubated for 30 min in a 30°C water bath. The reaction was terminated by rapid filtration and radioactivity measured by liquid scintillation spectrometry.
The affinity of ketamine for dopamine D 2 receptors was reported in a recent letter-to-the-editor in response to an issue germane to this topic.
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Results
Under the experimental conditions described we observed a clear demarcation between the high-and low-affinity states of the receptors. The addition of 200 M Gpp[NH]p showed no effect on the low-affinity states, while the high-affinity states were totally eliminated, thus validating the experimental conditions (see Figure 1 , data for the dopamine D 2 receptors shown).
Ketamine had an affinity (K i of 1.0 ± 0.2 M for the dopamine D 2 receptors (using [ 3 H]raclopride and striatal tissue) and an affinity of 0.5 ± 0.2 M (using cloned receptors and [
3 H]-dopamine). This was comparable to its affinity for the NMDA receptors labeled with [ 3 H]MK-801 (0.5 ± 0.15 M). Ketamine also showed appreciable affinity for the high-affinity state of the serotonin 5-HT 2 receptors (15 ± 5 M) (Figure 2 ). When S-ketamine was compared to its racemic mixture in parallel runs, S-ketamine showed a two-to three-times higher affinity for both the high-state of the dopamine PCP showed a similar high-affinity for the highaffinity state of the serotonin 5-HT 2 receptors (5 ± 2 M), as it did for the NMDA receptor as labeled with [ 3 H]MK-801 (2 ± 0.5 M) (Figure 3 ). And while its affinity for the D 2 receptor was relatively lower (37 ± 10 M), it is still high enough to preclude selectivity at clinically relevant concentrations.
When cloned D 2 receptors were exposed to ketamine and PCP they showed a significant, dose-dependent increase in the binding of 4). This increase was selective for CHO cells expressing the D 2 receptors and was not seen in cells without D 2 receptors. The increase for ketamine was in the range of 80% of that produced by dopamine, while that of PCP was in the range of 50% of the dopamine effect, suggestive of a partial agonist effect in this functional assay. The addition of raclopride dose-dependently (EC 50 2-5 nM) reversed this incorporation induced by ketamine and PCP, consistent with this incorporation being mediated selectively via the D 2 receptor.
Discussion
The results show that ketamine and PCP show an affinity for dopamine D 2 and serotonin 5-HT 2 receptors which is in the same range as their affinity for the NMDA receptor. Further, ketamine and PCP differentiate between the high-affinity state and the low-affinity state of these receptors, suggesting an agonist-like binding to these sites, a fact supported by their agonist-like action leading to enhanced incorporation of [ 35 S]GTP-␥-S in cloned CHO cells expressing D 2 receptors. These findings confound the inferences one can draw from the ketamine and PCP-based animal models of schizophrenia and drug discovery. We discuss these implications below.
While it has been very well recognized that challenge with ketamine and PCP leads to a broad-based perturbation of neurotransmitter systems, 10, 11 it has usually been assumed that these effects were secondary to a primary glutamatergic alteration. 5 However, this specificity is being challenged on several fronts. It is now documented that ketamine has a direct and relevant affinity (47 M) for the dopamine transporter (as measured using cloned receptors and [ 3 H]dopamine) and this effect shows stereoselectivity (S-more potent than Molecular Psychiatry R-ketamine). 15, 25 Further, it shows relevant affinity (19 M) for the serotonin transporter as assessed using [ 3 H]paroxetine. 26, 27 Similarly relevant affinities have been shown for PCP at the biogenic amine uptake site, in addition to its affinity for the NMDA-PCP site.
14 The actions are not limited to these systems, and recently it has been shown using recombinant opioid receptors expressed in CHO cells that ketamine shows a stereospecific high-affinity (pKi 4.4 M at the opioid receptor; 4.5 M at the opioid receptor and 3.6 M at the ␦ opioid receptor), well within the clinically relevant concentrations.
Despite an extensive search we could not find a study that had systematically examined the effects of ketamine and PCP on dopamine D 2 and serotonin 5-HT 2 receptors. The nearest relevant evidence is a paper by Nabeshima et al that showed that PCP in vitro, like ritanserin, protected 5-HT 2 receptors from inactivation by sulfhydryl-modifying-agent, N-ethylmaleimide, suggesting that PCP interacts directly with the 5-HT 2 receptor site. 13 It is important to point out that ketamine and PCP exhibited a high (and comparable to NMDA) affinity only for the high-affinity state of the D 2 and 5-HT 2 receptors and showed a much lower affinity (Ͼ100 M) for the low-affinity state of these receptors. This ability of ketamine and PCP to differentiate between high-and low-affinity states of the GPCR is characteristic of agonist-like ligands, suggesting that while ketamine and PCP are antagonists at the NMDA receptor site, they may function as agonists at the D 2 and 5-HT 2 site. This finding was confirmed at the D 2 site, by showing that ketamine and PCP led to significant [ 35 S]GTP-␥-S incorporation, specific to cells expressing the D 2 receptors, and could be competitively blocked by raclopride alone-suggesting that it was a partial agonist effect mediated via dopamine D 2 receptors.
The non-specificity of ketamine and PCP may not be limited to these receptors alone as preliminary data in our laboratory suggest that they have a similarly highaffinity (K i in the 1-10 M range) for the high state of the dopamine D 1 receptors and the adrenergic ␣1 receptors (unpublished data, further studies in progress).
It is important to note that while the affinities of ketamine and PCP for the dopamine D 2 and serotonin 5-HT 2 are in the M range, these are the functionally relevant concentrations of the use of these drugs in human and animal models. Ketamine has been used extensively as an anesthetic agent and the plasma concentrations associated with subanesthetic psychosislike perceptual disturbances are in the range of 0.5-1 M, 28 and with anesthesia setting in at concentrations in the 10-100 M range. [29] [30] [31] Further, brain concentrations are known to be several fold higher than plasma concentrations, 32 suggesting that even the subanesthetic psychosis-like perceptual disturbances occur only at brain concentrations in the one to few micromolar range. Since the affinities of ketamine for the NMDA receptors as well as for the dopamine D 2 and serotonin 5-HT 2 are relevant in this M range, this would make a selective disruption of NMDA transmission by these agents unlikely.
This nonspecificity of ketamine and PCP poses some challenges for the use of these agents as 'models' of schizophrenia. Ketamine and PCP administration in humans lead to perceptual and cognitive abnormalities and schizophrenia-like disturbances reminiscent of the 'positive' and 'negative' symptoms of schizophrenia. 8 It is commonly argued that the similarity between the drug-induced state and schizophrenia provides some evidence for a 'primary hypoglutamate' state in schizophrenia. 8, 33, 34 However, at the concentrations employed in human models, these drugs are not only likely to have an effect on the NMDA receptor system, but are also likely to have relevant effects on several G-protein coupled-receptors (notably D 2 and 5-HT 2 as well as monoamine transporters 15, 25 and the opioid receptor system. 35 In fact, more recent studies suggest that ketamine and PCP lead to a state of increased, as opposed to decreased, glutamatergic transmission further calling into question the use of these agents as models of the 'hypoglutamate' hypothesis. 36, 37 Ketamine and PCP are more commonly used in animal models to produce a state of hyperlocomotion or disruption of sensorimotor gating. This altered state is more effectively reversed by the administration of 'atypical' rather than 'typical' antipsychotics. This has led to the suggestion that these models, by recapitulating the hypoglutamate state of schizophrenia, are a better model to identify 'atypical' antipsychotics. 38 There are several caveats to this line of reasoning. First, the claim that ketamine/PCP models accurately distinguish typical from atypical antipsychotic drugs is not always substantiated in animal studies as several experiments show that typical antipsychotics can equally well block the effects of ketamine and PCP. 39, 40 More importantly, studies in patients with PCP-induced psychosis (the state that the animal models are presumably reflecting) show that typical antipsychotics such as haloperidol and pimozide (a selective D 2 / 3 blocker) are much more effective than placebo, and result in remission of all symptoms. [41] [42] [43] To our knowledge there are no data on the use of atypical antipsychotics in clinical PCPinduced psychosis.
Our finding would suggest that ketamine and PCP (especially as compared to the more conventional apomorphine/amphetamine model) would likely lead to a more widespread and non-specific neurochemical perturbation which would encompass direct and indirect changes in the glutamate, dopaminergic and serotonergic systems. Thus, one would expect that drugs which have a more widespread (and nonspecific) pharmacology would be more effective in this model, regardless of whether they are 'typical' or 'atypical'; and for that matter regardless of whether they are antipsychotic or not. This seems to be the case. Chlorpromazine (a typical antipsychotic with broadspectrum neurotransmitter actions including anti-serotonin effects) has been shown to be as effective as clozapine and olanzapine (atypical antipsychotics with several actions including anti-serotonin effects). 39 Conversely, amisulpiride (an atypical antipsychotic with no action on the serotonin system) is ineffective in these models, 44 even though it is clinically an 'atypical' antipsychotic. 45 Consistent with our findings, a recent analysis suggests that activity in ketamine/PCP vs amphetamine/apomorphine models segregates largely along 5-HT 2 vs D 2 lines: drugs with a potent action on the serotonin 5-HT 2 system being more effective in the PCP model; 44, 46 while drugs with a prominent action on the D 2 receptor being more effective in the apomorphine/amphetamine models; 44 and drugs with a mixed action being effective in both 44 regardless of whether these drugs are antipsychotic or not. 44 For example, fananserin (a 5-HT 2 /D 4 antagonist), MDL 100,907 (a selective 5-HT 2 antagonist), prazosin (a selective adrenergic ␣ 1 antagonist) are effective in the ketamine/PCP models 44, [47] [48] [49] [50] even though these drugs fail to show antipsychotic activity in the clinic. 51, 52 Several limitations of our findings and their implications need to be stated. The study is based on the affinity of ketamine and PCP for the high-affinity state of the D 2 and 5-HT 2 receptors, as it is this state of the receptor that is thought to be functionally important. 16 However, the high-affinity states are sensitive to experimental conditions, 21 therefore, the implications hold only insofar as the in vitro measurements reflect the status of high states in vivo. Secondly, our data should not be read to question the direct effect of ketamine and PCP as non-competitive NMDA receptor antagonists. This is a well established point and consistent with this direct effect, allosteric modifications of the NMDA receptor can reverse some actions of PCP in animal models. 53 Thus, we do not question the direct effect, just its selectivity at relevant doses. Third, while we have shown a direct effect on the dopamine D 2 and serotonin 5-HT 2 receptors in vitro, it is yet to be determined which of the behavioural effects of these challenges are attributable to these direct effects. It should be mentioned that at present the data on this issue are conflicting. Some aspects of these challenges can be reversed by D 2 blockers, 40, [54] [55] [56] some by 5-HT 2 blockers, [57] [58] [59] and some are not. 56 Finally, even if ketamine and PCP are non-specific in vivo, it does not invalidate the ketamine/PCP as models for studying schizophrenia. It could well be that schizophrenia itself is a multi-transmitter dysfunction and ketamine and PCP, by virtue of their relatively broad-based neurotransmitter perturbation, provide a better model of the complexity of this illness than a primary dopaminergic or a primary hypoglutamate model. Whether this is indeed the case cannot be unequivocally decided until the true nature of the neurochemical dysfunction in schizophrenia is delineated.
In summary, the data in this study suggest that ketamine and PCP, in addition to being non-competitive NMDA receptor antagonists, have a high-affinity for the dopamine D 2 and the serotonin 5-HT 2 site and act as partial agonists at the D 2 receptor. These findings question the inferences that can be drawn from ketamine and PCP challenges in animal models and patients.
More selective NMDA receptor antagonists are needed to advance the study of the role of the glutamate system in schizophrenia and antipsychotic action.
